Skip to content

The Next Generation of LAA Closure is Taking Shape

The Conformal Left Atrial Appendage Closure Implant is designed to conform to each patient’s unique anatomy, to be intuitive to use and to reduce the need for anticoagulation.

Our Focus

Conformal is focused on reducing strokes in patients with atrial fibrillation.

We are guided by the principle that left atrial appendage closure provides an important alternative to long-term oral anticoagulation, a strategy without long-term bleeding side effects or daily medications.

device

Our Goal

To advance left atrial appendage closure (LAAC) to a first-line strategy for stroke prevention by simplifying the procedure, improving the implant and delivery system, and eliminating the need for general anesthesia.

Large Addressable Market

About 6 million people in the United States are affected by atrial fibrillation. Of those, 64.5% are recommended for oral anticoagulants to reduce their risk of Afib-associated stroke. However, 12.5% are contraindicated for oral anticoagulants. As a result, the addressable market for left atrial appendage closure is over 700,000 patients.

3-6 million Afib patients in the US

3-6 million Afib patients in the US1

3-6 million Afib patients in the US1

64.5% of Afib patients are recommended for OAC

64.5% of Afib patients are recommended for OAC2

64.5% of Afib patients are recommended for OAC2

12.5% of Afib patients are contraindicated for oral anticoagulants

12.5% of Afib patients are contraindicated for oral anticoagulants3

12.5% of Afib patients are contraindicated for oral anticoagulants3

About 700,000 patients

About 700,000 patients

About 700,000 patients

Facts and Figures

About 33 million people globally are affected by atrial fibrillation. These people are five times more likely to experience stroke than the general population, and 90% of the clots leading to these strokes form in the left atrial appendage. The annual cost to treat atrial fibrillation in the United States is about $6 billion.

33 million people globally are affected by atrial fibrillation (Afib)

33 million people globally are affected by atrial fibrillation (Afib)4

33 million people globally are affected by atrial fibrillation (Afib)4

Afib patients are 5x more likely to experience stroke than the general population

Afib patients are 5x more likely to experience stroke than the general population5,6

Afib patients are 5x more likely to experience stroke than the general population5,6

In people with Afib, more than 90% of clots that lead to stroke form in the left atrial appendage

In people with Afib, more than 90% of clots that lead to stroke form in the left atrial appendage7

In people with Afib, more than 90% of clots that lead to stroke form in the left atrial appendage7

The annual cost of Afib treatment to the US healthcare system

The annual cost of Afib treatment to the US healthcare system8

The annual cost of Afib treatment to the US healthcare system8